Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 5,040
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:30 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

adcock ingram holdings ltd (AIP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/28/15 - $5,730
52 Week Low
01/22/15 - $4,046
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

adcock ingram holdings ltd (AIP) Related Businessweek News

View More BusinessWeek News

adcock ingram holdings ltd (AIP) Details

Adcock Ingram Holdings Limited manufactures, markets, and distributes medicines and healthcare products primarily in Sub-Saharan Africa and India. It offers a portfolio of prescription medicines, generic products, critical care, over-the-counter and consumer products, intravenous solutions, blood collection products, and renal dialysis systems. The company provides pharmaceutical products in a range of therapeutic classes, such as women’s health, antiretroviral, dermatology, central nervous system, respiratory, ophthalmic, cardiovascular, urology, pain, mental health, gastrointestinal, infections, pain and inflammation, colds and flu, personal care, supplements and energy, feminine hygiene, and digestive well-being. It also manufactures and supplies hospital and critical care products, including intravenous fluids, renal dialysis systems, products for the storage of blood and blood components, infusion systems, and accessories, as well as a range of wound care and ostomy products. Adcock Ingram Holdings Limited was founded in 1890 and is headquartered in Midrand, South Africa.

Founded in 1890

adcock ingram holdings ltd (AIP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: R813.0K
Deputy Chief Executive, Financial Director, E...
Total Annual Compensation: R3.9M
Compensation as of Fiscal Year 2014.

adcock ingram holdings ltd (AIP) Key Developments

Adcock Ingram Declares a Final Gross Dividend for the Year Ended June 30, 2015, Payable on September 21, 2015

Adcock Ingram's board has declared a final gross dividend out of income reserves of 81 cents per share in respect of the year ended June 30, 2015. The South African dividend tax rate is 15% and the net dividend payable to shareholders who are not exempt from DT is 68.85 cents per share. Last date to trade cum distribution is September 11, 2015; shares trade ex-distribution is September 14, 2015; record date is September 18, 2015; and payment date is September 21, 2015.

Adcock Ingram Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Adcock Ingram reported audited consolidated earnings results for the year ended June 30, 2015. In the year, the company recorded revenues of ZAR 5.558 billion compared to ZAR 5.234 billion a year ago, up 6.2% year on year against the comparable period of fiscal 2014. The company noted that revenue growth was driven by a variety of factors, including manufacturing efficiencies, lower costs of raw materials, and drug price increases in South Africa. Operating profit was ZAR 344.658 million compared to operating loss of ZAR 798.214 million a year ago. Profit before taxation was ZAR 339.840 million compared to loss before taxation of ZAR 835.945 million a year ago. Profit attributable to owners of the parent was ZAR 197.932 million or 117.2 cents per diluted share compared to loss attributable to owners of the parent of ZAR 832.533 million or 493.4 cents per diluted share a year ago. Basic and diluted headline earnings per ordinary share were 160.1 cents compared to basic and diluted headline loss per ordinary share of 100.8 cents a year ago. Net cash inflow from operating activities was ZAR 427.486 million compared to ZAR 29.312 million a year ago. Purchase of property, plant and equipment was ZAR 23.560 million compared to ZAR 35.727 million a year ago.

COSME Farma Reportedly On The Block

COSME Farma Laboratories Ltd. has been put up for sale by Adcock Ingram Holdings Limited (JSE:AIP). The asking price is set at INR 4.8 billion. Adcock Ingram said it will kick-start the sale process soon. In an official statement along with its corporate results for the last financial year, Adcock said: “South African business did well and showed improved profitability; the rest of Africa and Indian businesses continue to post losses. Downsides included a further impairment of ZAR 74.4 million to Cosme business in India. As a result, the board has resolved to dispose of this investment at the earliest opportunity and a formal sale process will soon be started for this purpose.”


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AIP:SJ 5,040.00 0.00

AIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AIP.
View Industry Companies

Industry Analysis


Industry Average

Valuation AIP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADCOCK INGRAM HOLDINGS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at